Xcout IntelSign inSubscribe

Embold Therapeutics, Inc. competitors & alternatives

BiotechnologyUnited States

The 12 closest competitors and alternatives to Embold Therapeutics, Inc. among biotechnology companies — ranked by similarity to what Embold Therapeutics, Inc. actually does, not by market-cap band.

12Competitors listed

Subscribe to see Embold Therapeutics, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event

About Embold Therapeutics, Inc.

Embold Therapeutics, Inc. is a life-sciences company located in Redwood City, California.

Embold Therapeutics, Inc. at a glance

Embold Therapeutics, Inc. is a biotechnology company headquartered in United States. It has raised at least $4.8M across the 2 funding rounds on record. Its most recent funding round, Series B, raised $2.3M in July 2026. Xcout tracks 6 named people at Embold Therapeutics, Inc., including Gjalt Huisman (CEO).

Embold Therapeutics, Inc. leadership

  • Gjalt HuismanCEO
  • Gjalt W. HuismanChief Executive Officer
  • Daniel SteinFounder and CEO
  • Vesna MitchellHead of Molecular Biology Research Operations
  • Victoria WongHead of Translational Sciences
  • Gjalt W. HuismanExecutive Officer

Embold Therapeutics, Inc. funding rounds

At least $4.8M raised across the 2 rounds on record. Every round on record:

DateRoundAmountInvestors
Series B$2.3M4 named
SEC Form D filing$2.5M—

Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →

Recent Embold Therapeutics, Inc. news

Top 12 Embold Therapeutics, Inc. competitors

Ranked by semantic similarity — how close each company is to Embold Therapeutics, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.

Bolt Biotherapeutics, Inc.BOLT · BiotechRedwood City, United States
69% matchPublic

Biotech

Bolt Biotherapeutics, Inc. is a biotechnology company currently conducting clinical trials, focused on developing innovative immuno-oncology therapies. Its mission is to create agents that equip the body's immune system to identify and eliminate cancerous cells. A key therapeutic in its pipeline is BDC-1001, an investigational treatment targeting the human epidermal growth factor receptor 2 (HER2). This compound is presently undergoing Phase I/II clinical evaluation for patients with HER2-positive solid tumors, including those exhibiting low HER2 expression. Beyond BDC-1001, the company is advancing several other programs: BDC-2034, which targets carcinoembryonic antigen for various indications such as colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody designed to reprogram crucial immune cells within the tumor microenvironment by interacting with macrophage cell-surface receptors. Bolt is also pursuing a programmed cell death-ligand 1 (PD-L1) initiative aimed at addressing tumors that prove resistant to existing immune checkpoint blockades. Incorporated in 2015 under its previous name, Bolt Therapeutics, Inc., before officially becoming Bolt Biotherapeutics, Inc. in July of the same year, the company maintains its corporate headquarters in Redwood City, California.

Market cap$7.9M
Employees52
Bolt Biotherapeutics, Inc. competitors & alternatives →

Analyze another company

Search any company we track to see its competitive set.

Or describe a company

Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.

See the full profile of Embold Therapeutics, Inc. and its market

Funding, investors, tech stack, hiring signals, leadership and corporate events — for Embold Therapeutics, Inc.and every competitor above — in one live dashboard.

Subscribe to Xcout Intel →